Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Yakutskenerg reported for 6 months of 2023 by IFRS

8/29/23 YKEN

Sakhalinenergo reported for 6 months of 2023 by IFRS

8/29/23 SLEN

Segezha Group reported for 6 months of 2023 by IFRS

8/29/23 SGZH

Globaltrans reported for 6 months of 2023

8/29/23 GLTR

KuibyshevAzot reported for 6 months of 2023 by IFRS

8/29/23 KAZT

Medsi's revenues grew by 15.7% in the first half of the year

8/29/23 AFKS

Kazanorgsintez reported for 6 months of 2023 by IFRS

8/28/23 KZOS

Krasny Kotelshchik reported for 6 months of 2023 by IFRS

8/28/23 KRKO

Rosseti Kuban reported for 6 months of 2023 by IFRS

8/28/23 KUBE

Nizhnekamskneftekhim reported for 6 months of 2023 by IFRS

8/28/23 NKNC